253 related articles for article (PubMed ID: 14552702)
21. Inflammation and Alzheimer's disease.
Lee YJ; Han SB; Nam SY; Oh KW; Hong JT
Arch Pharm Res; 2010 Oct; 33(10):1539-56. PubMed ID: 21052932
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
23. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
24. Drugs targeting Alzheimer's disease: some things old and some things new.
Michaelis ML
J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
[TBL] [Abstract][Full Text] [Related]
25. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
26. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
27. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.
Yokota O; Terada S; Ishihara T; Nakashima H; Kugo A; Ujike H; Tsuchiya K; Ikeda K; Saito Y; Murayama S; Ishizu H; Kuroda S
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):715-21. PubMed ID: 15276698
[TBL] [Abstract][Full Text] [Related]
28. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
[TBL] [Abstract][Full Text] [Related]
29. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
Harel Z
J Pediatr Adolesc Gynecol; 2004 Apr; 17(2):75-9. PubMed ID: 15050982
[TBL] [Abstract][Full Text] [Related]
31. Non-steroidal anti-inflammatory drugs protect amyloid beta protein-induced increase in the intracellular Cl- concentration in cultured rat hippocampal neurons.
Iwata R; Kitagawa K; Zhang NY; Wu B; Inagaki C
Neurosci Lett; 2004 Sep; 367(2):156-9. PubMed ID: 15331142
[TBL] [Abstract][Full Text] [Related]
32. The brain as a target for inflammatory processes and neuroprotective strategies.
Skaper SD
Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
[TBL] [Abstract][Full Text] [Related]
33. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Lang S; Zeidler R
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):41-8. PubMed ID: 14552703
[TBL] [Abstract][Full Text] [Related]
34. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Howard PA; Delafontaine P
J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
[TBL] [Abstract][Full Text] [Related]
35. COX-2 inhibition as a tool to treat and prevent colorectal cancer.
Tuynman JB; Peppelenbosch MP; Richel DJ
Crit Rev Oncol Hematol; 2004 Nov; 52(2):81-101. PubMed ID: 15501074
[TBL] [Abstract][Full Text] [Related]
36. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
37. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
Monsuez JJ
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms.
Halliday G; Robinson SR; Shepherd C; Kril J
Clin Exp Pharmacol Physiol; 2000; 27(1-2):1-8. PubMed ID: 10696521
[TBL] [Abstract][Full Text] [Related]
39. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.
Hoozemans JJ; Rozemuller JM; van Haastert ES; Veerhuis R; Eikelenboom P
Curr Pharm Des; 2008; 14(14):1419-27. PubMed ID: 18537664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
